Briacell's Bria-IMT study receives no safety concerns

Executive Summary

• Briacell Therapeutics received its fourth consecutive positive recommendation from the independent Data Safety Monitoring Board (DSMB) regarding the safety of its pivotal Phase 3 study.
• The study evaluates Bria-IMT combined with an immune checkpoint inhibitor for the treatment of metastatic breast cancer (NCT06072612).
• The DSMB raised no safety concerns and recommended the study continue without modifications, reinforcing the safety and tolerability profile of the Briacell regimen.

Key Details

• Study Phase: Pivotal Phase 3.
• Indication: Metastatic Breast Cancer.
• Investigational Product: Bria-IMT plus an immune checkpoint inhibitor.
• Clinical Trial Identifier: NCT06072612.
• DSMB Outcome: Fourth consecutive positive recommendation; no safety concerns raised; study to continue without modifications.
• Regulatory Status: The study is conducted under Fast-Track Designation granted by the U.S. Food and Drug Administration (FDA).
• DSMB Schedule: Meetings occur quarterly in accordance with the study protocol.
• Management Commentary: CEO Dr. William V. Williams highlighted the "excellent safety and tolerability profile" and the potential to transform cancer care for patients with urgent medical needs.

Notable Quotes

• "Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the Briacell regimen," commented Dr. William V. Williams, Briacell's president and chief executive officer.
• "We strongly believe in Bria-IMT's potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs."